Business

Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors

Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AMarch 22, 20263/news/announcement-on-voluntary-disclosure-of-receipt-of-clinical-trial-approval-notice-for-bl-arc002-in-the-treatment-of-advanced-solid-tumors
Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A